Spanish Red Biotech Pipeline

MSD

MK1308A (quavonlimab+pembro)

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Multicenter,Multi Arm,Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants w/Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
Phase: 2Phase II in Spain, 1Phase I